InsiderTrades.com logo
David Malcom Rodman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Rodman Biography and Net Worth

Chief Medical Officer of Mineralys Therapeutics

David Rodman, M.D. has served as our Chief Medical Officer since January 2021. Previously, Dr. Rodman served in various roles at miRagen, Vertex Pharmaceuticals Inc., and Novartis Institutes for BioMedical Research. Dr. Rodman was elected to the American Society for Clinical Investigation and named an Established Investigator and Fellow of the American Heart Association. Dr. Rodman received his medical degree from the University of Pennsylvania and was subsequently Board Certified in Internal Medicine, Pulmonary Medicine and Critical Care Medicine at the University of Colorado.

What is David Malcom Rodman's net worth?

The estimated net worth of David Malcom Rodman is at least $1.49 million as of April 14th, 2025. Dr. Rodman owns 111,686 shares of Mineralys Therapeutics stock worth more than $1,489,891 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Rodman may own. Additionally, Dr. Rodman receives an annual salary of $726,950.00 as Chief Medical Officer at Mineralys Therapeutics. Learn More about David Malcom Rodman's net worth.

How old is David Malcom Rodman?

Dr. Rodman is currently 69 years old. There are 3 older executives and no younger executives at Mineralys Therapeutics. Learn More on David Malcom Rodman's age.

What is David Malcom Rodman's salary?

As the Chief Medical Officer of Mineralys Therapeutics, Inc., Dr. Rodman earns $726,950.00 per year. The highest earning executive at Mineralys Therapeutics is Mr. Jon Congleton, CEO & Director, who commands a salary of $775,770.00 per year. Learn More on David Malcom Rodman's salary.

How do I contact David Malcom Rodman?

The corporate mailing address for Dr. Rodman and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at investorrelations@mineralystx.com. Learn More on David Malcom Rodman's contact information.

Has David Malcom Rodman been buying or selling shares of Mineralys Therapeutics?

During the last ninety days, David Malcom Rodman has sold $1,044,098.94 in shares of Mineralys Therapeutics stock. Most recently, David Malcom Rodman sold 11,366 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $14.53, for a transaction totalling $165,147.98. Following the completion of the sale, the insider now directly owns 111,686 shares of the company's stock, valued at $1,622,797.58. Learn More on David Malcom Rodman's trading history.

Who are Mineralys Therapeutics' active insiders?

Mineralys Therapeutics' insider roster includes Jon Congleton (CEO), Adam Levy (Chief Financial Officer), and David Rodman (Chief Medical Officer). Learn More on Mineralys Therapeutics' active insiders.

Are insiders buying or selling shares of Mineralys Therapeutics?

In the last twelve months, Mineralys Therapeutics insiders bought shares 2 times. They purchased a total of 1,896,296 shares worth more than $25,599,996.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 880,592 shares worth more than $11,566,301.71. The most recent insider tranaction occured on April, 14th when insider David Malcom Rodman sold 11,366 shares worth more than $165,147.98. Insiders at Mineralys Therapeutics own 33.2% of the company. Learn More about insider trades at Mineralys Therapeutics.

Information on this page was last updated on 4/14/2025.

David Malcom Rodman Insider Trading History at Mineralys Therapeutics

See Full Table

David Malcom Rodman Buying and Selling Activity at Mineralys Therapeutics

This chart shows David Malcom Rodman's buying and selling at Mineralys Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$1.04MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

Mineralys Therapeutics Company Overview

Mineralys Therapeutics logo
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $13.34
Low: $12.90
High: $13.97

50 Day Range

MA: $12.92
Low: $8.76
High: $16.87

2 Week Range

Now: $13.34
Low: $8.24
High: $18.38

Volume

822,303 shs

Average Volume

427,959 shs

Market Capitalization

$865.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A